

MedAnnex secures further investment for the development of its novel monoclonal antibody to treat autoimmune diseases.

Edinburgh, Scotland. 20th December 2015.

MedAnnex Limited, an innovative Scottish biotechnology company working in the field of novel autoimmune disease therapies, today announced that it has completed a financing round to expedite the ongoing development programme for its new antibody Annexuzlimab®.

The investment will enable MedAnnex to prepare for the first clinical trial of the antibody. It will also allow the company to expand its core capabilities and drive value-creating strategies for intellectual property and collaborations.

In laboratory studies, Annexuzlimab® has shown significant potential as a therapeutic in several autoimmune diseases, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.

Professor Chris Wood, Chairman of MedAnnex, said: “We are delighted to have completed this significant financing round for MedAnnex. Our results to date suggest that Annexuzlimab® could have enormous potential for autoimmune disease therapy, and this funding is vital for the development of our exciting new antibody.”

About MedAnnex

MedAnnex Ltd, based in Scotland, is a dynamic biotechnology company developing new treatments for people with autoimmune diseases.

About Annexuzlimab®

Annexuzlimab®, MedAnnex’s lead product, is a humanised monoclonal antibody. Its target is annexin-1, which is over-expressed in autoimmune disease and is a key factor in the human immune system. Blocking annexin-1 with Annexuzlimab®, in experimental models, has reversed the progression of several autoimmune diseases.